With expertise in preclinical ophthalmology, advanced surgical techniques, and retinal gene therapy, Dr. Ryan Boyd delivers innovative solutions for the development of therapeutics and medical devices.

Endpoint Preclinical is proud to welcome Dr. Ryan Boyd, DVM, MS, DACVO, to our Expert Network. A board-certified veterinary ophthalmologist, Dr. Boyd specializes in preclinical ophthalmology and retinal gene therapy. His work supports the development of therapeutics and medical devices through innovative surgical techniques, robust experimental design, comprehensive data analysis and interpretation, and precise reporting—ensuring high-quality, reproducible results for clients. View Ryan’s Profile

Dr. Boyd’s expertise spans a wide range of advanced ophthalmic surgical techniques critical to preclinical research. His precision in subretinal and intravitreal injections ensures the targeted delivery of gene therapies and pharmacologic agents, while his proficiency in intraocular device implantation allows for comprehensive safety, tolerability, and efficacy evaluations. Additionally, Dr. Boyd has mastered techniques such as vitrectomy and suprachoroidal delivery, offering cutting-edge approaches for ocular therapeutic applications.

In the realm of retinal gene therapy, Dr. Boyd brings exceptional skill in optimizing gene delivery protocols. By refining subretinal and intravitreal injections, he ensures efficient and precise transgene expression, essential for evaluating therapeutic outcomes. His ability to correlate advanced imaging data with histopathological findings enables detailed analysis, interpretation, and reporting of treatment effects, delivering actionable insights for preclinical programs.

Dr. Boyd’s technical toolkit includes a range of advanced imaging and diagnostic modalities. These include Optical Coherence Tomography (OCT) for high-resolution retinal layer analysis, Electroretinography (ERG) to assess functional retinal activity, Fundus Photography for documenting structural changes over time, and many others. Together, these tools enable detailed monitoring and data-driven decision-making for ocular therapeutics.

At Endpoint, Dr. Boyd will play a vital role in onsite surgical assistance, protocol development, study design, and data reporting/interpretation. A dedicated mentor, he has led training programs to advance research teams’ precision in advanced ophthalmic procedures. His focus on standardizing techniques and refining data collection methods ensures consistency, reproducibility, and high-quality outcomes across translational ocular research.

Dr. Boyd’s work supports diverse preclinical research applications, from evaluating gene therapy for retinal diseases to testing intraocular medical devices for safety and functionality. His expertise also strengthens pharmacologic safety assessments, where precise data interpretation and reporting are critical to meeting regulatory and scientific standards.

We are excited to have Dr. Boyd’s innovative skillset and experience as part of the Endpoint Preclinical team. His contributions will enhance our ability to deliver cutting-edge solutions for ocular research, gene therapy, and medical device development.

Join us in welcoming Dr. Ryan Boyd to Endpoint Preclinical. To learn how his expertise can support your next preclinical program, Contact us today.